Figure 2. In vivo anti-tumor activity of BIIG2.
(A) Athymic nude mice were xenografted with patient-derived melanoma cells (labeled M15 and M12) from brain metastasis. Upon observation of palpable tumors, we proceeded with the treatment of the mice. Illustration created with BioRender.com. (B) Mice were injected intraperitoneally with BIIG2 or other αv and α5 integrin antibodies. Treatment was administered twice weekly at a dose of 10 mg/kg. Data plotted are shown as means ± SEM; n=10 per day of measurement. Tumor volumes on the final day of observation were plotted as mean ± SEM; n=10, except for M15 where IgG control n=9. A one-way ANOVA with Bonferroni correction was performed for statistical significance of the complete antibody panel against the control IgG, adjusted P values are shown. Comparisons between BIIG2 and the panel of antibodies were analyzed in the same method in Figure 5A. (C) Pentamidine isethionate, an aromatic diamidine with anti-cancer activity, was administered intraperitoneally at a dose of 10 mg/kg once daily. Data shown are mean ± SEM; n=10 mice per treatment group; one-way ANOVA with Bonferroni correction; adjusted P values are shown. The clinically tested MINT1526A could not be used for comparison due to a shortage of purified antibody, which was kindly provided by Genentech. See also Figures S4 and S5.